NCT05829434 (MAGROLIC) is a Phase 2 clinical trial of Magrolimab in Acute Myeloid Leukemia, sponsored by Uwe Platzbecker.

Who is sponsoring NCT05829434?

NCT05829434 is sponsored by Uwe Platzbecker.

What drugs are being tested in NCT05829434?

Interventions in NCT05829434: Magrolimab, 7+3, CPX-351.

What condition does NCT05829434 study?

NCT05829434 studies Acute Myeloid Leukemia, Myelodysplastic Neoplasm.

Is NCT05829434 still recruiting?

NCT05829434 is currently withdrawn. Last updated 12 February 2024.

Last reviewed 2024-02-12 · How we verify

NCT05829434: MAGROLIC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS

Withdrawn Phase 2 Last updated 12 February 2024

What this trial tests

Phase 2 trial testing Magrolimab in Acute Myeloid Leukemia. Withdrawn.

Timeline

31 March 2024

Primary endpoint
30 August 2028

30 August 2029

Quick facts

Lead sponsor	Uwe Platzbecker
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Start date	31 March 2024
Primary completion	30 August 2028
Estimated completion	30 August 2029

Drugs / interventions tested

Magrolimab — full drug profile →
7+3 — full drug profile →
CPX-351 (cpx-351) — full drug profile →

Conditions studied

Acute Myeloid Leukemia — all drugs for Acute Myeloid Leukemia →
Myelodysplastic Neoplasm — all drugs for Myelodysplastic Neoplasm →

Sponsor

Uwe Platzbecker — full company profile →

Who can join

18 and older, any sex, with Acute Myeloid Leukemia or Myelodysplastic Neoplasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Use of magrolimab in combination with standard intensive chemotherapy ("7+3" or CPX-351) in newly diagnosed "ELN 2022 intermediate or adverse-risk" AML or high risk MDS patients, who intend to undergo allogeneic stem cell transplantation

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Checkpoint inhibition in hematologic malignancies.
Tsumura A, Levis D, Tuscano JM. · · 2023 · cited 14× · PMID 37920162 · DOI 10.3389/fonc.2023.1288172
CD47-Targeted Therapy in Cancer Immunotherapy: At a Crossroads of Promise and Challenge.
Guo X, Fu Y, Baran N, Ma W. · · 2025 · cited 4× · PMID 41179296 · DOI 10.32604/or.2025.071708
Metabolic reprogramming of efferocytosis in the tumour microenvironment: From apoptotic-cell clearance to therapeutic targeting.
Yang Q, Yan J, Yang Q. · · 2026 · cited 1× · PMID 41601343 · DOI 10.1002/ctm2.70601

Verify or expand the search:

Other trials of Magrolimab

Trials testing the same drug.

NCT05367401 — A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants · Phase 1, PHASE2 · withdrawn
NCT05823480 — Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS · Phase 1 · withdrawn
NCT05807126 — Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of · Phase 1 · withdrawn
NCT06046482 — Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous C · Phase 2 · terminated
NCT05929716 — An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell · Phase 2 · withdrawn

Other recruiting trials for Acute Myeloid Leukemia

Currently open trials in the same condition.

NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
NCT06782542 — Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for I · Phase 2 · recruiting
NCT07177079 — High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML · Phase 1 · recruiting
NCT07384715 — First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelod · Phase 1 · recruiting
NCT07107126 — Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05829434 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Uwe Platzbecker
Last refreshed: 12 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05829434.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing